Neurological Institute Outcomes
Multiple Sclerosis
Multiple Sclerosis — Focus on Early Treatment to Improve Disease Control
Numerous clinical trials have shown that disease modifying therapies (DMTs) for MS can decrease disease activity. Many barriers can slow initiation of DMT including obtaining insurance authorization, preliminary testing, and locating an infusion site for intravenous medication. The Mellen Center is working to decrease the "Time to First Dose" in patients initiating a DMT.
Patients Starting Natalizumab and Days to First Dose
2020 – 2021
Patients Starting Ocrelizumab and Days to First Dose
2020 – 2021
Patients on Ocrelizumab Who Participated in a Shared Medical Visit
2021
The Mellen Center has developed a shared medical visit for patients starting ocrelizumab. The visit is scheduled prior to the first ocrelizumab infusion and its purpose is to help patients know what to expect and make sure that all prerequisites have been fulfilled for them to receive the medication.
